Image credit: shutterstock
Shenzhen Eureka Biotechnology Co. (EurekaBio), a leading upstream supplier in the cell and gene therapy field, has announced the completion of its Series B+ financing, exceeding $40 million. The financing was led by YUEXIU INDUSTRIAL FUND, with participation from numerous well-known Chinese funds, as well as follow-on investments from US funds.
The funds will support the commercial implementation of large-scale production technology for Lentiviral Vectors (LVV), advance research and development around large-scale production technology for Adeno-Associated Viral Vectors (AAV), promote comprehensive solutions for cell therapy manufacturing, accelerate global market expansion efforts, and bolster the overall growth of the company.
EurekaBio's core innovation lies in the EuLV Lentiviral Vector Production System, a cutting-edge technology that transforms the large-scale production of lentiviral vectors using stable cell lines and a serum-free suspension system.
Additionally, EurekaBio has developed an automated solution tailored for the complete spectrum of cell therapy manufacturing processes involving cell isolation, magnetic bead cultivation, viral transduction, cell expansion, concentration, washing formulation and packaging.
